Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck’s Mevacor Switch Bid Digs Deeper Into Consumers’ Self-Selection

This article was originally published in The Tan Sheet

Executive Summary

Merck's self-selection study developed to support its latest Mevacor OTC switch application will bolster its bid by providing deeper insight into consumers' selection decisions, the firm says

Related Content

FDA Expects OTC Switch Self-Selection Studies To Probe Consumer Thinking
Crestor Indication Grows User Pool, But Self-Selection Hinders Statin Switch
FDA Advisors Say Greater Insight Needed On Self-Selection Of OTC Statins
GSK Gets OTC Mevacor U.S. Marketing Rights In Agreement With Merck
Merck’s Mevacor Returns For OTC Switch Consideration
Merck’s Mevacor Returns For OTC Switch Consideration
Alli Marketing Stresses Education, With Emphasis On Minority Groups – GSK
NDAC Calls For Predefined Endpoints In Consumer Behavior Trials
Merck Regroups On Mevacor Switch; Could CUSTOM Analysis Pave The Way?
Mevacor OTC Panel Rejection Elicits Third Drug Class Talk





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts